Eli Lilly and Company

Other

Eli Lilly

Michael Philip Cohen

Frantz Victor

John M Schaus

Steven Armen Boyd

Deyi Zhang

Yao-Chang Xu

Sandra Ann Filla

Daniel Timothy Kohlman

Bai-Ping Ying

DeAnna Piatt Zacherl

Sarah Lynne Hellman

Matthew Joseph Fisher

Bruno Giethlen

Jefferson Ray McCowan

Sidney Xi Liang

Shawn Christopher Miller

Zhaogen Chen

James Ronald Gillig

Michael Wade Tidwell

Michael Philip Mazanetz

Michael J Rodriguez

Peter Thaddeus Gallagher

John Gordon Allen

Barry P Clark

Andrew Caerwyn Williams

Christopher Stanley Galka

Patrick Gianpietro Spinazze

Karin Briner

Brian Michael Mathes

Sean Patrick Hollinshead

Maria Ann Whatton

Maria Angeles Martinez-Grau

Maria-Jesus Blanco-Pillado

Vincent Mancuso

Roger Ryan Rothhaar

Matthew Robert Reinhard

Kevin John Hudziak

Dana Rae Benesh

Marta Maria Pineiro-Nunez

Anne Marie Camp

Valentina O Badescu

Arundhati S Deo

Wai-Man Lee

Christopher Stephen Siedem

Deanna Piatt Zacherl

John Mehnert Schaus

Jefferson Ray Mccowan

Michael John Rodriguez

Richard Gerard Conway

Barry Peter Clark

The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where;  The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

[object Object]

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently &#x2014;C(H)&#x2550; or &#x2014;N&#x2550;, provided that at least one of A and B is &#x2014;N&#x2550;, n is 1-3, m is 0-3, and R1-4 are as defined herein.

2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists

The present invention provides selective 5-HTreceptor antagonist compounds of Formula I and their use in the treatment of migraine: 

The present invention provides compounds of formula (I), which are antagonists of the 5-HTreceptor. 

N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: 

The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; Ris C-Calkyl, substituted C-Calkyl, C-Ccycloalkyl, substituted C-Ccycloalkyl, C-Ccycloalkyl-C-Calkyl, substituted C-Ccycloalkyl-C-Calkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C-Calkyl, C-Ccycloalkyl-C-Calkyl, or a group of formula II  Ris hydrogen or C-Calkyl; Ris hydrogen, halo, or C-Calkyl; Ris hydrogen or C-Calkyl; Ris hydrogen or C-Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R&#x2550; or N&#x2550;; Ris C&#x2013;Calkyl, substituted C&#x2013;Calkyl, C&#x2013;Ccycloalkyl, substituted C&#x2013;Ccycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; Ris hydrogen, C&#x2013;Cn-alkyl, C&#x2013;Ccycloalkyl-C&#x2013;Calkyl, or a group of formula II (II) provided that when Ris C&#x2013;Calkyl or substituted C&#x2013;Calkyl, Ris hydrogen or methyl; R, R, and, when X is C(R)&#x2550;, R, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R, R, and Rmay be other than hydrogen; Ris hydrogen or C&#x2013;Calkyl; Ris hydrogen, C&#x2013;Calkyl, or C&#x2013;Ccycloalkylcarbonyl, provided that when Ris other than hydrogen, Ris hydrogen; Ris hydrogen or C&#x2013;Calkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTreceptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. 

The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HTreceptor. The present invention further provides a method of treating disorders associated with 5-HTreceptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

A clothing garment is formed in two loops or bands as unitary garment. A first of the two loops is an elongated member and the second is an elongated, non-rectangular member, having a wide central region. The two loops can be in the form of two pieces of fabric sewn or otherwise bonded together to form two joined loops. The loops can be elongated pieces of fabric formed into loops by a releasable closure member, such as a hook and loop connector. The connector can provide size adjustment to accommodate various head sizes. The loop with the wide central region is shorter than the essentially rectangular loop.

Article of clothing

Growing community of inventors

Indianapolis, IN, United States of America

Michael Philip Cohen